298 trends tracked about this subject — the full history, oldest to newest below.
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Recent coverage details how a weight-loss drug class improves knee osteoarthritis pain across multiple trials and reviews.
Pfizer secures up to $1.5 billion from Blackstone Life Sciences to advance a once-monthly GLP-1 obesity treatment acquired from Metsera.
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
New research suggests popular GLP-1 weight-loss medications may influence brain health, prompting medical debate over expanding their use beyond diabetes and obesity.
The FDA warns that widely used GLP-1 medications like Ozempic and Zepbound carry a potential risk of vision loss.
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
The Food and Drug Administration mandates safety label changes for GLP-1 medications following potential rare eye condition risks.
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
Hims & Hers Health reported Q3 2026 revenue of $401.6 million, up 69% year over year, but narrowed its full-year revenue guidance and cut its adjusted EBITDA forecast, sending shares down sharply.
Federal regulators issue a new warning regarding GLP-1 medications and a rare eye condition linked to sudden blindness.
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.
A small Adelaide University sheep study found a single dose of semaglutide cut maternal cardiac output and fetal oxygen levels within two hours, raising new questions about GLP-1 drug safety during pregnancy.
A 40-week study found that resistance training helped people taking tirzepatide lose 25% less lean tissue while improving strength by 10%.
Insurers are cutting coverage for GLP-1 weight-loss drugs, with coverage dropping from 57% to 53% between 2025 and 2026, while list prices range from $500 to over $1,000 monthly.
Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.
Recent reporting examines the challenges of weight maintenance and patient adherence after stopping GLP-1 medications.
Eli Lilly has struck a deal allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on its platform.
10 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Novo Nordisk raises its 2026 outlook and shares surge as the Wegovy weight-loss pill rollout accelerates.
Recent coverage examines nutritional deficiencies linked to weight-loss injections and highlights the importance of protein intake.
2 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
Eli Lilly stock reaches an all-time high amid surging GLP-1 sales and a heightened price target.
Coverage explores unexpected side effects, mental health impacts, and generational patterns surrounding GLP-1 medications.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Employer health plans are increasingly dropping GLP-1 weight-loss drug coverage as cash prices soar and 2027 options remain uncertain.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New research suggests a synergy between hormone therapy and GLP-1 weight-loss medications for women navigating menopause.
An investigational triple-action weekly weight-loss drug significantly reduces obstructive sleep apnea severity in late-stage clinical trials.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
FDA moves to curb bulk compounding of GLP‑1 weight‑loss drugs as legal action hits telehealth firm HIMS
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
19 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent studies link popular GLP-1 weight-loss drugs to unexpected dermatological side effects like nail detachment and hair loss.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent coverage links GLP-1 medications like Ozempic and Wegovy to legal action involving vision loss alongside contrasting studies.
Walmart expands employee health benefits to include free GLP-1 drugs and hundreds of medications.
A growing wave of coverage examines newly reported links between popular GLP-1 medications and rare instances of severe vision loss.
Unapproved weight loss drug retatrutide faces a booming black market linked to multiple reported deaths and severe side effects.
Obesity drugs face a major pivot as clinical trials investigate their potential to treat addiction, depression, and criminal behavior.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent reporting examines whether GLP-1 weight-loss medications could help women conceive and boost fertility outcomes.
Recent coverage examines what happens when individuals stop taking GLP-1 weight loss and diabetes medications.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Early research indicates GLP-1 weight-loss drugs may slow biological aging by up to four years, according to recent coverage.
Federal regulators face mounting scrutiny as unapproved weight-loss drugs and new safety warnings enter public focus.
Recent scientific findings point to potential methods for limiting weight regain after patients stop taking GLP-1 medications.
Recent studies indicate that popular GLP-1 weight-loss medications like Ozempic and Mounjaro may also slow biological aging.
Recent coverage examines the rising use of GLP-1 medications among children, highlighting strong weight loss alongside nutritional and data gaps.
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
15 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Ongoing legal actions and international reports highlight severe risks linked to weight-loss drugs.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.